2020.01.10

FY02/2020 Q3 Results Earnings Release Presentation

2020.01.10

Announcement of Establishment of New Company in Malaysia

2020.01.09

Notification of the commencement of Phase III clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)

2019.12.16

Notification of marketing of HARUROPI® TAPE in Japan (Transdermal, Parkinson’s disease treatment patch, development code: HP-3000)(116KB)

2019.11.26

Notification of the results of Phase II clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)(106KB)